CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Argentina

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Argentina

  • October 2017 •
  • 147 pages •
  • Report ID: 5206658 •
  • Format: PDF
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Argentina

Pharmaceutical market increased from over US$3 Billion in 2009 to around US$6.5 Billion in 2016, at a Compound Annual Growth Rate (CAGR) of nearly 10%. It is expected to cross US$10 Billion in 2021 at a CAGR of about 10%. In 2009, the medical device market was valued at just over US$1 Billion. It grew at a CAGR of 4% between 2009 and 2016 and reached around US$1.3 Billion. It is expected to grow at a CAGR of about 5%, from around US$1.4 Billion in 2017 to over US$1.7 Billion in 2021.

Argentina is the third-largest pharmaceutical market in Latin America after Brazil and Mexico. With a relatively low-cost base and high-quality professionals in the biotechnology sector, Argentina is home to over 130 biotechnology companies. It is considered a favorable source for cost-effective clinical trials within Latin America. It is one of the first Latin American countries to implement the recommendations of the World Health Organization (WHO) Good Manufacturing Practices and Control standards, which endorse compliance to an international set of quality standards for pharmaceutical production.

Between 2009 and 2016 the population increased at a CAGR of 1.2% to 43.60 million. Between 2017 and 2021, it is forecast to increase at a CAGR of around 1.1% to 46.13 million. The 15-64 and 65-and-above age groups accounted for the largest portions of the population, and their percentage is expected to increase by 2021, indicating that the overall life expectancy for males and females will continue to increase over the next decade. This means that the percentage of inhabitants at risk of acquiring medical aliments will also increase. This has been a factor in the double-digit growth of the market.

Argentina is one of South America’s largest economies. It has a well-educated workforce and is rich in natural resources. In 2016, its GDP per capita was estimated to be more than US$12,000. It is forecast to cross US$18,000 in 2021. A new government was elected in 2015 and has implemented policies aimed at slashing public spending, opening Argentina’s doors to foreign investment and lifting currency controls.

The report "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Argentina", provides an overview of the pharmaceutical and medical device market of Argentina, including the market size; market segmentation by generic, Over-The-Counter (OTC), biologic and biosimilar products; and the key drivers and barriers for the market. The section also includes profiles of the major companies, including a SWOT assessment.

In depth, this report provides the following analysis -
- Covers the country’s reimbursement and payer landscape, as well as the regulatory landscape. The reimbursement and payer landscape section elaborates on the features of the healthcare reimbursement process for Argentina.
- Includes details of the reimbursement process, insurance providers, pricing policies and drug price trends. The regulatory landscape section provides an overview of the regulatory agencies and approval processes for new drugs and medical devices.
- Provides a detailed analysis of the political and economic environment of Argentina. It analyzes its economic indicators, demographics, healthcare infrastructure and healthcare expenditure.
- Provides an overview of the opportunities and challenges for growth that exist in the healthcare market of Argentina.

The report provides information on the healthcare, regulatory, and reimbursement landscape in Argentina, and includes -
- An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
- Profiles and SWOT analyses of the major players in the pharmaceutical market: Roemmers, Bago, Gador, Bayer and Pfizer; and of major players in the medical device market: Sonova, Siemens Healthineers, GN Hearing, Cochlear and William Demant Holding
- An insightful review of the reimbursement and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices
- Detailed analysis of the country’s political and economic environment, covering economic indicators, demographics, healthcare infrastructure and healthcare expenditure
- An overview of the opportunities for and challenges to growth in the Argentina’s healthcare market

Reasons to buy
This report will enhance your decision-making capability by allowing you to -
- Develop business strategies by understanding the trends shaping and driving Argentina’s healthcare market
- Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments and companies likely to impact Argentina’s healthcare market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance
- Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment and strategic partnership

We are very sorry, but an error occurred.
Please contact if the problem remains.